Prolor Biotech (PBTH -2%) says it's initiated Phase III clinical trials of hGH-CTP, a human...

|By:, SA News Editor

Prolor Biotech (PBTH -2%) says it's initiated Phase III clinical trials of hGH-CTP, a human growth hormone that provides deficient adults and children with hGH therapy that may require only once-weekly or bi-monthly injections, rather than the daily injections required by current hGH therapy.